IndiCell - Individualized pluripotent stem cell-based therapy
| Reference number | |
| Coordinator | Lunds universitet - Lunds universitet Biomedicinskt Centrum |
| Funding from Vinnova | SEK 39 999 932 |
| Project duration | October 2021 - September 2026 |
| Status | Ongoing |
| Venture | Innovationsmiljöer inom precisionshälsa |
| Call | Innovation milieus in precision Health 2021 |
Important results from the project
IndiCell largely achieved its objectives. The Parkinson’s disease model project transplanted eight patients and published the first clinical follow-up, while the macular degeneration therapy reached regulatory clearance ahead of a clinical trial. The project established a reusable development pipeline covering reprogramming, cell washing, cell sorting and single-cell-based quality control, while also generating patents, publications, industrial collaborations and new Swedish ATMP infrastructure
Expected long term effects
IndiCell is expected to shorten and de-risk translation of pluripotent stem-cell therapies from research to patients. Reusable processes, regulatory knowledge, quality-control methods and new ATMP/GMP infrastructure can reduce development time, risk and cost while strengthening Swedish clinical implementation and commercialisation. Networks, patents, follow-on projects and trained expertise provide a durable foundation for more accessible advanced therapies and stronger Swedish competitiveness.
Approach and implementation
IndiCell was implemented through six work packages involving academia, healthcare and industry. Central management, committed WP leaders, regular digital meetings and in-person retreats ensured coordination, follow-up and problem-solving. The project followed the plan, while complex technology development required flexible reprioritization. Doctoral students led internal communication and retreat planning. The stable partnership was characterized by clear responsibilities, openness and trust